Open AcceEditorial How to compare antivirals in the treatment of chronic hepatitis B?

After the use of antiviral drugs in the treatment of hepatitis B virus (HBV) infection, we found new therapeutic options for non-responders to interferon (IFN). Addition-ally, those could not be treated previously by IFN, such as cirrhotics have been given effective antivirals. However, the parameters to determine the efficacy, the outcome measures, and the duration of the treatment emerged as unresolved issues by the treatment with antivirals. Resist-ance to antivirals is also a challenge and its definition, detection, and management are new controversial topics in the area of HBV treatment. Now, the clinician has a wider choice of antivirals: in addition to IFNs, lamivudine, adefovir, entecavir, telbivu-dine, and tenofovir have been approved for treating chronic HBV infection [1,2]. As the HBV treatment studie